Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 2/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 3/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1907185 | 0.88 | AKT1 (0.41) | PDE2ASSTR4AKT1AKT2 | |
| SCHEMBL1905333 | 0.84 | TACR3 (0.36) | PDE2ATACR3SSTR4SCN9ACYP3A4 | |
| SCHEMBL1903687 | 0.83 | CHEK1 (0.40) | PDE2ACHEK1 | |
| SCHEMBL1903720 | 0.82 | PDE2A (0.34) | PDE2ATACR3SSTR4SCN9AAKT1 | |
| SCHEMBL1902469 | 0.81 | AKT1 (0.47) | AKT1AKT2 | |
| SCHEMBL14118764 | 0.80 | TACR3 (0.42) | MEN1KMT2ATACR3CYP3A4CYP2C8 | |
| SCHEMBL1907804 | 0.80 | PDE2A (0.34) | PDE2AMEN1HSP90AA1KMT2ATACR3 | |
| SCHEMBL14119440 | 0.78 | PDE2A (0.40) | PDE2ATACR3 | |
| SCHEMBL1903877 | 0.78 | MAPK14 (0.46) | PDE2ATACR3SCN9AAKT1 | |
| SCHEMBL1905736 | 0.77 | MEN1 (0.32) | MEN1HSP90AA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | PDE2A 2363/4885MEN1 1472/4885HSP90AA1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.